Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Thoratec VAD

This article was originally published in The Gray Sheet

Executive Summary

Ventricular assist device PMA supplement submission to FDA is anticipated by year-end to support a therapeutic recovery indication to reverse late-stage heart failure in certain patients as a viable alternative to transplantation. The device currently is approved for use as a bridge to cardiac transplantation and postcardiotomy recovery of the natural heart. Overall sales of the system increased nearly 40% in the first quarter ended April 1, as the company added ten new treatment centers (five in the U.S. and five internationally) to end the quarter with 140 centers. Corporate sales for the three months increased 41.5% to $7.6 mil., compared to $5.4 mil. in the same period one year ago. Net income of $649,000 compares to a loss of $336,000 in the first quarter of 1999
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT013320

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel